TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: WebQuit Online Smoking Cessation Study
Brief Summary: Would you like to quit smoking?

Seattle's Fred Hutchinson Cancer Research Center is launching a new study that may be able to help. Participants who enroll in this study will be randomly assigned by computer (like flipping a coin) to one of two online programs. The goal of this study is to learn which of these programs is the most effective at helping people stop smoking. Findings from this study will be used to help build more effective online smoking cessation programs in the future.

Participants in both of the smoking cessation programs used in this study will receive:

* Interactive tools for dealing more effectively with urges to smoke
* Step-by-step guides for quitting smoking
* Personalized plans for quitting and remaining smoke-free
* Electronic links for reaching one-on-one expert help for quitting

Participants will be asked to complete online questionnaires, including a brief three-month follow-up survey.

There is no cost for participating in this study.

To enroll in this study or for more information, please visit www.webquit.com.

This study is being conducted by Seattle's Fred Hutchinson Cancer Research Center (www.fhcrc.org), a world leader in advancing the prevention, diagnosis and treatment of cancer. The principal investigator for the WebQuit smoking cessation study is Dr. Jonathan Bricker, a faculty member at both the Hutchinson Center and at the University of Washington in Seattle.


Options:
A: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P
B: Arm Label: WebQuit study group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: WebQuit study group | Arm Label: WebQuit control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: WebQuit control group | Intervention Type: BEHAVIORAL; Name: WebQuit study group; Assigned to Arm(s): WebQuit study group | Intervention Type: BEHAVIORAL; Name: WebQuit control group; Assigned to Arm(s): WebQuit control group
C: Arm Label: Participants; Type: N/A; Interventions: N/A
D: Arm Label: Mindfulness-Based Treatment Group (MBAT); Type: EXPERIMENTAL; Interventions: Behavioral: MBAT Group Therapy, Drug: Nicotine | Arm Label: Standard Care Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine, Behavioral: Group Therapy | Arm Label: Usual Care Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine, Behavioral: Individual Therapy | Intervention Type: BEHAVIORAL; Name: MBAT Group Therapy; Assigned to Arm(s): Mindfulness-Based Treatment Group (MBAT) | Intervention Type: DRUG; Name: Nicotine; Assigned to Arm(s): Mindfulness-Based Treatment Group (MBAT), Standard Care Group, Usual Care Group | Intervention Type: BEHAVIORAL; Name: Group Therapy; Assigned to Arm(s): Standard Care Group | Intervention Type: BEHAVIORAL; Name: Individual Therapy; Assigned to Arm(s): Usual Care Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Examining a Text Message Intervention for Smoking Cessation
Brief Summary: The primary goal of this study is to use qualitative interviews and focus groups to aid us in adapting a face-to-face smoking cessation intervention for delivery through text messaging. After design is completed, the intervention will be pilot tested with a sample of young adults (ages 18-35) who smoke. Final assessments will be conducted at 7 weeks (end of treatment) and both 3 and 6 month follow up.


Options:
A: Arm Label: Experimental App; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental App | Arm Label: Active comparator app; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Comparator App | Intervention Type: BEHAVIORAL; Name: Experimental App; Assigned to Arm(s): Experimental App | Intervention Type: BEHAVIORAL; Name: Active Comparator App; Assigned to Arm(s): Active comparator app
B: Arm Label: SMS Turkey; Type: EXPERIMENTAL; Interventions: Behavioral: SMS Turkey | Arm Label: Brochure control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SMS Turkey; Assigned to Arm(s): SMS Turkey
C: Arm Label: Crush the Crave Application; Type: EXPERIMENTAL; Interventions: Behavioral: Crush the Crave Application | Arm Label: On the Road to Quitting - Self Help; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: On the Road to Quitting - Self Help | Intervention Type: BEHAVIORAL; Name: Crush the Crave Application; Assigned to Arm(s): Crush the Crave Application | Intervention Type: BEHAVIORAL; Name: On the Road to Quitting - Self Help; Assigned to Arm(s): On the Road to Quitting - Self Help
D: Arm Label: Text Messaging; Type: EXPERIMENTAL; Interventions: Behavioral: text messaging for smoking cessation | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Generic text messages | Intervention Type: BEHAVIORAL; Name: text messaging for smoking cessation; Assigned to Arm(s): Text Messaging | Intervention Type: BEHAVIORAL; Name: Generic text messages; Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Examining a Text Message Intervention for Smoking Cessation
Brief Summary: The primary goal of this study is to use qualitative interviews and focus groups to aid us in adapting a face-to-face smoking cessation intervention for delivery through text messaging. After design is completed, the intervention will be pilot tested with a sample of young adults (ages 18-35) who smoke. Final assessments will be conducted at 7 weeks (end of treatment) and both 3 and 6 month follow up.


Options:
A: Arm Label: Crush the Crave Application; Type: EXPERIMENTAL; Interventions: Behavioral: Crush the Crave Application | Arm Label: On the Road to Quitting - Self Help; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: On the Road to Quitting - Self Help | Intervention Type: BEHAVIORAL; Name: Crush the Crave Application; Assigned to Arm(s): Crush the Crave Application | Intervention Type: BEHAVIORAL; Name: On the Road to Quitting - Self Help; Assigned to Arm(s): On the Road to Quitting - Self Help
B: Arm Label: Experimental App; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental App | Arm Label: Active comparator app; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Comparator App | Intervention Type: BEHAVIORAL; Name: Experimental App; Assigned to Arm(s): Experimental App | Intervention Type: BEHAVIORAL; Name: Active Comparator App; Assigned to Arm(s): Active comparator app
C: Arm Label: Text Messaging; Type: EXPERIMENTAL; Interventions: Behavioral: text messaging for smoking cessation | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Generic text messages | Intervention Type: BEHAVIORAL; Name: text messaging for smoking cessation; Assigned to Arm(s): Text Messaging | Intervention Type: BEHAVIORAL; Name: Generic text messages; Assigned to Arm(s): Control
D: Arm Label: Lifestyle counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Tabac Info Service | Arm Label: Current practices; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tabac Info Service; Assigned to Arm(s): Lifestyle counseling

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Late Clinical Events After Drug-eluting Versus Bare-metal Stents in Patients at Risk: BAsel Stent Kosten Effektivitäts Trial - PROspective Validation Examination Part II (BASKET-PROVE II)
Brief Summary: Background:

Retrospective analyses of long-term BASKET findings identified patients with large drug-eluting stents (DES) (\>2.5mm Stents) as patients at risk for late cardiac death/nonfatal myocardial infarction. In view of new DES with absorbable polymers and new bare metal stents BMS) with thin struts and biocompatible polymers, BP-II will be launched to test their comparative clinical safety up to 12 years if treated with an aspirin/prasugrel combination, since prasugrel halved stent thrombosis rates compared to clopidogrel in a large ACS trial.

The primary objective is to demonstrate non-inferiority of the Nobori DES stent compared to the Xience Prime DES stent on safety and e cacy in patients requiring stents \>=3.0mm in diameter on the background of contemporary dual antiplatelet therapy (DAPT) with prasugrel and aspirin

Set-up:

Multicenter open-label randomized trial.

Patient inclusion:

Unselected series of patients in need of large (\>3mm) stents only in native vessels irrespective of clinical indication.

Patient exclusion:

In-stent restenosis, Left-main disease, cardiogenic shock, planned surgery \<12months, increased bleeding risk, no compliance expected, History of stroke or transient ischemic attack (TIA).

Randomization:

By centre using sealed envelopes 1:1:1: Nobori:Xience Prime:Prokinetik-stent.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: drug-eluting stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: bare-metal stent | Intervention Type: DEVICE; Name: drug-eluting stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: bare-metal stent; Assigned to Arm(s): 2
B: Arm Label: XIENCE V®; Type: EXPERIMENTAL; Interventions: Device: XIENCE V® Everolimus Eluting Coronary Stent | Arm Label: TAXUS™ EXPRESS2™; Type: ACTIVE_COMPARATOR; Interventions: Device: TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent | Intervention Type: DEVICE; Name: XIENCE V® Everolimus Eluting Coronary Stent; Assigned to Arm(s): XIENCE V® | Intervention Type: DEVICE; Name: TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent; Assigned to Arm(s): TAXUS™ EXPRESS2™
C: Arm Label: Everolimus-eluting stent; Type: ACTIVE_COMPARATOR; Interventions: Device: Everolimus-eluting stent | Arm Label: Bare-metal stent; Type: ACTIVE_COMPARATOR; Interventions: Device: Bare-metal stent | Arm Label: Biodegradable Polymer-DES; Type: EXPERIMENTAL; Interventions: Device: Biodegradable Polymer-DES | Intervention Type: DEVICE; Name: Everolimus-eluting stent; Assigned to Arm(s): Everolimus-eluting stent | Intervention Type: DEVICE; Name: Bare-metal stent; Assigned to Arm(s): Bare-metal stent | Intervention Type: DEVICE; Name: Biodegradable Polymer-DES; Assigned to Arm(s): Biodegradable Polymer-DES
D: Intervention Type: DRUG; Name: Angiomax (bivalirudin) anticoagulant; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Multicenter Study to Compare the Efficacy of Additional Tumor Debulking Surgery vs Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
Brief Summary: It is still not clear whether a positive AGO-score just selects patients with less aggressive biologic tumor behavior who as well would have had a positive outcome by chemotherapy only, or , if it is a score selecting patients who really benefit from surgery. Nevertheless, the AGO-score was confirmed to select patients with a less than 30% risk of ending with residual tumor after surgery for recurrent disease. This could avoid including patients into the present surgical protocol who could not benefit from an operationThe goal of this third DESKTOP study is to evaluate in a prospectively randomized multicentre setting, whether maximum effort of cytoreductive surgery followed by platinum based combination chemotherapy can improve overall survival as compared to platinum based combination chemotherapy alone in AGO-score positive patients.


Options:
A: Arm Label: Control Arm - Chemotherapy only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Procedure/Surgery; Type: EXPERIMENTAL; Interventions: Procedure: Tumor Debulking Surgery (surgery in recurrent ovarian disease) | Intervention Type: PROCEDURE; Name: Tumor Debulking Surgery (surgery in recurrent ovarian disease); Assigned to Arm(s): Procedure/Surgery
B: Arm Label: Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Rucaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Rucaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Cediranib, Drug: Olaparib | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Cediranib, Drug: Olaparib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Arm B, Arm C | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Arm B, Arm C
D: Arm Label: Olaparib 300mg tablets; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match olaparib 300mg | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib 300mg tablets | Intervention Type: DRUG; Name: Placebo to match olaparib 300mg; Assigned to Arm(s): Placebo tablets

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: COMPARISON OF CLINICAL EFFICACY OF COMBINATION Amoxycillin Plus Clavulanic Acid and Oxacillin Plus Ceftriaxone for HOSPITAL TREATMENT OF COMMUNITY Acquired PNEUMONIA IN CHILDREN : A Randomized Clinical Study
Brief Summary: Objective: To compare the clinical effectiveness and hospital costs, the initial empirical treatment, Oxacillin / Ceftriaxone and Amoxicillin / Clavulanate in children with Community Acquired Pneumonia (CAP) severe.

Methods: Clinical prospective randomized study in children aged two months to five years of age with a diagnosis of severe CAP, according to criteria of World Health Organization (WHO), admitted to the Pediatrics Ward of the Hospital of the Medical School of Botucatu- UNESP. We excluded children with comorbid disorders (primary and secondary immunodeficiency) with acute or chronic kidney disease, referred patients receiving antibiotics proposal and history of allergy to antibiotics proposed. We included 104 children who were randomized into two groups to receive: Oxacillin / Ceftriaxone IV (GCO, n = 48) and Amoxicillin / Clavulanate IV (GAA, n = 56). Patients of the GAA, after clinical improvement, has been receiving the same oral antibiotic, and maintaining clinical stability, were discharged from hospital, the GOC received any IV treatment. The outcomes analyzed were time to clinical improvement (fever and tachypnea), duration of oxygen therapy, hospitalization time, need to expand the antimicrobial spectrum progression to pleural effusion / empyema (DP / E) and hospital costs. Treatment failure was determined by the need to expand the antimicrobial spectrum after 48 hours of hospitalization.


Options:
A: Arm Label: amoxicillin/clavulanic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxycillin/clavulanic acid | Arm Label: ceftriaxone/oxacillin; Type: ACTIVE_COMPARATOR; Interventions: Drug: ceftriaxone/oxacillin | Intervention Type: DRUG; Name: Amoxycillin/clavulanic acid; Assigned to Arm(s): amoxicillin/clavulanic acid | Intervention Type: DRUG; Name: ceftriaxone/oxacillin; Assigned to Arm(s): ceftriaxone/oxacillin
B: Intervention Type: DRUG; Name: Levofloxacin; Assigned to Arm(s): N/A
C: Arm Label: Intervention; Type: OTHER; Interventions: Drug: Amoxicillin | Arm Label: Control; Type: OTHER; Interventions: Other: Referral to Health facility | Intervention Type: DRUG; Name: Amoxicillin; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Referral to Health facility; Assigned to Arm(s): Control
D: Intervention Type: DRUG; Name: Oral Co-trimoxazole (8mg/kg/day trimithoprim) twice a day for five days vs. oral amoxycillin (20 mg/kg/day) thrice a day for three days.; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Controlled Study Comparing EKOS EkoSonic Ultrasound Accelerated Thrombolysis to Anticoagulation in the Treatment of Sub-massive Pulmonary Embolism
Brief Summary: The ULTIMA study is intended to prove that in patients with pulmonary embolism and a right ventricular end diastolic diameter to left ventricular end diastolic diameter ratio ≥1 (RV/LV ratio) will benefit from treatment with ultrasound accelerated thrombolysis (rt-PA) as compared to unfractionated heparin anticoagulation. Specifically, at 24 hours the RV/LV ratio will be significantly reduced in the treatment arm compared to the control arm.


Options:
A: Arm Label: group A; Type: EXPERIMENTAL; Interventions: Drug: tenecteplase (group A) | Arm Label: group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo ( group B) | Intervention Type: DRUG; Name: placebo ( group B); Assigned to Arm(s): group B | Intervention Type: DRUG; Name: tenecteplase (group A); Assigned to Arm(s): group A
B: Intervention Type: DRUG; Name: tenecteplase; Assigned to Arm(s): N/A
C: Arm Label: A-Intervention; Type: EXPERIMENTAL; Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA) | Arm Label: B-Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant tissue plasminogen activator (rt-PA); Assigned to Arm(s): A-Intervention
D: Arm Label: Ultrasound accelerated thrombolysis; Type: EXPERIMENTAL; Interventions: Device: EkoSonic Endovascular System | Arm Label: Intravenous unfractionated heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Intervention Type: DEVICE; Name: EkoSonic Endovascular System; Assigned to Arm(s): Ultrasound accelerated thrombolysis | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Intravenous unfractionated heparin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Controlled Study Comparing EKOS EkoSonic Ultrasound Accelerated Thrombolysis to Anticoagulation in the Treatment of Sub-massive Pulmonary Embolism
Brief Summary: The ULTIMA study is intended to prove that in patients with pulmonary embolism and a right ventricular end diastolic diameter to left ventricular end diastolic diameter ratio ≥1 (RV/LV ratio) will benefit from treatment with ultrasound accelerated thrombolysis (rt-PA) as compared to unfractionated heparin anticoagulation. Specifically, at 24 hours the RV/LV ratio will be significantly reduced in the treatment arm compared to the control arm.


Options:
A: Arm Label: Ultrasound accelerated thrombolysis; Type: EXPERIMENTAL; Interventions: Device: EkoSonic Endovascular System | Arm Label: Intravenous unfractionated heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Intervention Type: DEVICE; Name: EkoSonic Endovascular System; Assigned to Arm(s): Ultrasound accelerated thrombolysis | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Intravenous unfractionated heparin
B: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Urokinase | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: Urokinase | Intervention Type: DRUG; Name: Urokinase; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Urokinase; Assigned to Arm(s): Group 2
C: Arm Label: A-Intervention; Type: EXPERIMENTAL; Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA) | Arm Label: B-Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant tissue plasminogen activator (rt-PA); Assigned to Arm(s): A-Intervention
D: Intervention Type: DRUG; Name: tenecteplase; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Controlled Study Comparing EKOS EkoSonic Ultrasound Accelerated Thrombolysis to Anticoagulation in the Treatment of Sub-massive Pulmonary Embolism
Brief Summary: The ULTIMA study is intended to prove that in patients with pulmonary embolism and a right ventricular end diastolic diameter to left ventricular end diastolic diameter ratio ≥1 (RV/LV ratio) will benefit from treatment with ultrasound accelerated thrombolysis (rt-PA) as compared to unfractionated heparin anticoagulation. Specifically, at 24 hours the RV/LV ratio will be significantly reduced in the treatment arm compared to the control arm.


Options:
A: Arm Label: EkoSonic® Endovascular System; Type: EXPERIMENTAL; Interventions: Drug: recombinant tissue plasminogen activator, Device: EKOS EkoSonic Endovascular System | Intervention Type: DRUG; Name: recombinant tissue plasminogen activator; Assigned to Arm(s): EkoSonic® Endovascular System | Intervention Type: DEVICE; Name: EKOS EkoSonic Endovascular System; Assigned to Arm(s): EkoSonic® Endovascular System
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: ALN optional filter | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: ALN optional filter; Assigned to Arm(s): 1
C: N/A
D: Arm Label: Ultrasound accelerated thrombolysis; Type: EXPERIMENTAL; Interventions: Device: EkoSonic Endovascular System | Arm Label: Intravenous unfractionated heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Intervention Type: DEVICE; Name: EkoSonic Endovascular System; Assigned to Arm(s): Ultrasound accelerated thrombolysis | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Intravenous unfractionated heparin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) Study
Brief Summary: This study will test an intervention program designed to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle to see if that intervention will prevent rapid weight gain in infancy and overweight at age 3 years. Further, compared with control infants, intervention infants will have lower body mass index (BMI) percentiles at age 3. The investigators also hypothesize that control infants will gain weight more rapidly over time.


Options:
A: Intervention Type: BEHAVIORAL; Name: Targeted parental instruction for positive lifestyle change with follow-up calls.; Assigned to Arm(s): N/A
B: Arm Label: Vouchers; Type: ACTIVE_COMPARATOR; Interventions: Other: Vouchers, Other: Nutrition education | Arm Label: Control; Type: OTHER; Interventions: Other: Nutrition education | Intervention Type: OTHER; Name: Vouchers; Assigned to Arm(s): Vouchers | Intervention Type: OTHER; Name: Nutrition education; Assigned to Arm(s): Control, Vouchers
C: Arm Label: Vegetable exposure; Type: EXPERIMENTAL; Interventions: Other: Vegetable exposure | Arm Label: VIPP-Feeding Infants; Type: EXPERIMENTAL; Interventions: Behavioral: VIPP-Feeding Infants | Arm Label: Exposure + VIPP-FI; Type: EXPERIMENTAL; Interventions: Other: Vegetable exposure, Behavioral: VIPP-Feeding Infants | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Vegetable exposure; Assigned to Arm(s): Exposure + VIPP-FI, Vegetable exposure | Intervention Type: BEHAVIORAL; Name: VIPP-Feeding Infants; Assigned to Arm(s): Exposure + VIPP-FI, VIPP-Feeding Infants | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
D: Arm Label: Parenting Insight; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Parenting Insights | Arm Label: Child Safety Insights; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Child Safety Insights | Intervention Type: BEHAVIORAL; Name: Child Safety Insights; Assigned to Arm(s): Child Safety Insights | Intervention Type: BEHAVIORAL; Name: Parenting Insights; Assigned to Arm(s): Parenting Insight

Answer: D